pDONR221-SLC1A3_STOP Citations (2)
Originally described in: The RESOLUTE consortium: unlocking SLC transporters for drug discovery.Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6. PubMed Journal
Articles Citing pDONR221-SLC1A3_STOP
| Articles |
|---|
| Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily. Digles D, Ingles-Prieto A, Dvorak V, Mocking TAM, Goldmann U, Garofoli A, Homan EJ, Di Silvio A, Azzollini L, Sassone F, Fogazza M, Barenz F, Pommereau A, Zuschlag Y, Ooms JF, Tranberg-Jensen J, Hansen JS, Stanka J, Sijben HJ, Batoulis H, Bender E, Martini R, IJzerman AP, Sauer DB, Heitman LH, Manolova V, Reinhardt J, Ehrmann A, Leippe P, Ecker GF, Huber KVM, Licher T, Scarabottolo L, Wiedmer T, Superti-Furga G. Front Pharmacol. 2024 Jul 9;15:1401599. doi: 10.3389/fphar.2024.1401599. eCollection 2024. PubMed |
| Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer. Koochaki P, Qiu B, Coker JA, Earsley A, Wang NS, Romigh T, Goins CM, Stauffer SR, Boudker O, Chakraborty AA. bioRxiv [Preprint]. 2025 Jul 7:2025.07.03.663021. doi: 10.1101/2025.07.03.663021. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.